Pharmafile Logo
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • - PMLiVE
  • Communiqué 53 Cover Image

Apogee Therapeutics

- PMLiVE

Ipsen to acquire Memo Therapeutics in deal worth more than €700m

The deal expands the company’s rare disease portfolio

- PMLiVE

Vertex to acquire Crinetics in deal worth around $10bn

The deal includes an approved treatment for acromegaly and other pipeline candidates

- PMLiVE

Novartis to acquire Myricx Bio in deal worth $1.5bn

Myricx, a UK-based biotech, is developing a new class of antibody-drug conjugates

- PMLiVE

Klick Health acquires Oxford PharmaGenesis

The move expands Klick’s scientific expertise in oncology and rare diseases

- PMLiVE

Zymeworks to acquire Theravance Biopharma in deal worth $929m

The acquisition will give the company access to a treatment for COPD

- PMLiVE

AbbVie to acquire Apogee Therapeutics in $10.9bn deal

The acquisition includes clinical-stage candidates for atopic dermatitis and asthma

- PMLiVE

Biogen to acquire RayThera in $1bn deal

The acquisition will expand the company’s immunology pipeline

- PMLiVE

Lilly to acquire LimmaTech Biologics and Vaccine Company in deals totalling $2.33bn

The acquisitions reinforce the company’s commitment to reduce the long-term burden of serious disease

- PMLiVE

Lilly to acquire Curevo in deal worth $1.5bn

The acquisition will help build Lilly’s infectious disease portfolio

- PMLiVE

Angelini Pharma to acquire Catalyst Pharmaceuticals for $4.1bn

Catalyst Pharmaceuticals is focused on novel medicines for rare diseases

- PMLiVE

Eli Lilly to acquire Kelonia Therapeutics in deal worth up to $7bn

The acquisition will help Lilly to expand its capabilities in cell and gene therapy

- PMLiVE

Allergan Aesthetics launches Skin Quality Index for aesthetic consultations

Spanning four dimensions of skin health, the framework introduces 15 terms and definitions

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links